Literature DB >> 30417563

Comparison of urinary cytology and fluorescence in situ hybridization in the detection of urothelial neoplasia: An analysis of discordant results.

Teresa McHale1,2, N Paul Ohori1, Kathy M Cieply1, Carol Sherer1, Sheldon I Bastacky1.   

Abstract

BACKGROUND: We examine the performance of cytology and FISH in the detection of urothelial carcinoma (UC), and explore the reasons for discrepant results, and potential clinical implications.
METHODS: Urine samples from 89 patients were prospectively collected for simultaneous cytology and UroVysion FISH, and results correlated with concurrent biopsies and/or clinical or histologic follow-up data. Corresponding tissue biopsies, where available, were also evaluated by FISH.
RESULTS: Sensitivity and specificity of cytology and FISH for the detection of UC was 54.8% and 92% and 50% and 88%, respectively. Only one of seven false-positive urinary FISH results proved to be an "anticipatory positive" on extended follow-up. Five of eight (62.5%) high grade (HG) carcinomas with false-negative urinary FISH, were negative due to the absence/paucity of FISH-detectable changes in the tumor cells. In atypical cytology cases, the FISH result did not assist in identifying UC. There was no significant difference between an atypical cytology result and a positive FISH result, with respect to the identification of patients with UC.
CONCLUSIONS: We found urinary cytology to be more sensitivity and specific than FISH in the detection of UC, though the difference was not statistically significant. Up to 24% of HG UCs are FISH negative due to an absence of FISH-detectable abnormalities in the tumor cells. Paucity of neoplastic cells in the urine also contributes to false-negative FISH results in both HG and low grade tumors. Negative urinary FISH cannot be taken alone as indicating the absence of significant disease in patients with atypical cytology.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  atypical cytology; bladder; false negative; fluorescence in situ hybridization; urothelial carcinoma

Mesh:

Year:  2018        PMID: 30417563     DOI: 10.1002/dc.24108

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  2 in total

1.  Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test.

Authors:  Niko Kavcic; Ivan Peric; Andreja Zagorac; Nadja Kokalj Vokac
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

Review 2.  Nephron-sparing management of upper tract urothelial carcinoma.

Authors:  Jason M Farrow; Sean Q Kern; Gustavo M Gryzinski; Chandru P Sundaram
Journal:  Investig Clin Urol       Date:  2021-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.